Short answer
Intellia Therapeutics, Inc. (NTLA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $7M (down 48.0% year over year) with net income of −$127M.
Q3 2026 key financials · XBRL
- Revenue
- $7M
- −48.0% YoY · −6.5% QoQ
- Net income
- −$127M
- −25.8% YoY · −19.6% QoQ
- Operating margin
- -1707.7%
- EPS (diluted)
- −$0.92
- −1.1% YoY · −15.0% QoQ
Source: XBRL data from the Intellia Therapeutics, Inc. (NTLA) Q3 2026 10-Q on SEC EDGAR. USD.
Intellia Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $7.2M, down $6.6M YoY from $13.8M
- Operating loss $122.3M vs $111.5M YoY, net loss $127.5M vs $101.3M
- Nex-z R&D $21.4M, highest program spend, up $1.5M; lonvo-z $10.2M, down $4.9M
- Cash, equivalents and marketable securities $614.8M; operating cash outflow $285.9M through nine months
- Lonvo-z BLA Priority Review, PDUFA date March 10, 2027; planned launch first quarter 2027 if approved
Risk Factors
- Newly added risk, FDA acceptance of lonvo-z BLA and Priority Review triggered uncertainty for first in vivo CRISPR therapeutic application, with PDUFA date March 10, 2027
- Most material update, MAGNITUDE and MAGNITUDE-2 clinical holds lifted in first quarter 2026 after Grade 4 liver injury and patient death
- Regulatory risk, FDA may impose extended follow-up, including a recommended 15-year observation period for genome-editing recipients
- Legal risk, PTAB again awarded CRISPR eukaryotic patent priority to Broad Institute on March 26, 2026, with UC/Vienna/Charpentier appeal pending
- Financial risk, September 2026 credit facility permits up to $400 million but requires minimum $50 million liquidity before lonvo-z BLA approval
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Intellia Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.